127 related articles for article (PubMed ID: 8070025)
1. Topoisomerase expression in cancer cell lines and clinical samples.
Doyle LA
Cancer Chemother Pharmacol; 1994; 34 Suppl():S32-40. PubMed ID: 8070025
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
5. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
6. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
[TBL] [Abstract][Full Text] [Related]
7. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo.
Prosperi E; Sala E; Negri C; Oliani C; Supino R; Astraldi Ricotti GB; Bottiroli G
Anticancer Res; 1992; 12(6B):2093-9. PubMed ID: 1338275
[TBL] [Abstract][Full Text] [Related]
9. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
10. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.
Evans CD; Mirski SE; Danks MK; Cole SP
Cancer Chemother Pharmacol; 1994; 34(3):242-8. PubMed ID: 8004758
[TBL] [Abstract][Full Text] [Related]
11. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.
Binaschi M; Giaccone G; Gazdar AF; De Isabella P; Ricotti GC; Capranico G; Zunino F
J Natl Cancer Inst; 1992 Nov; 84(22):1710-6. PubMed ID: 1331483
[TBL] [Abstract][Full Text] [Related]
13. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
McLeod HL; Douglas F; Oates M; Symonds RP; Prakash D; van der Zee AG; Kaye SB; Brown R; Keith WN
Int J Cancer; 1994 Dec; 59(5):607-11. PubMed ID: 7960233
[TBL] [Abstract][Full Text] [Related]
15. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
16. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
[TBL] [Abstract][Full Text] [Related]
17. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
19. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung cancer and topoisomerases.
Giaccone G
Anticancer Res; 1994; 14(1B):269-76. PubMed ID: 8166466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]